DEF 14AAKTXCIK 0001541157

Akari Therapeutics Plc

Name: SEC EDGAR filing 0001493152-26-045371
Creator: Akari Therapeutics Plc
License: https://www.usa.gov/government-works

Proxy statement (DEF 14A) filed October 1, 2026.

Definitive proxy statement disclosing matters to be voted on by shareholders, including executive compensation.

Open the filing on SEC.gov

New to the DEF 14A? What it is and how to read one

Filing facts

Accession number: 0001493152-26-045371
Filer: Akari Therapeutics Plc
Ticker: AKTX
CIK: 0001541157
Form type: DEF 14A
Form description: Proxy statement
Filed at: October 1, 2026
Industry: SIC 2834Pharmaceutical Preparations
Last verified: October 2, 2026SecFilingDex pulls from EDGAR with daily cadence

Provenance

Authoritative source — SEC EDGAR

https://www.sec.gov/Archives/edgar/data/1541157/000149315226045371/0001493152-26-045371-index.htm ↗

Filer's full EDGAR submission history

EDGAR · Akari Therapeutics Plc (0001541157) ↗

Machine-readable JSON twin (LLM-citation friendly)

/api/filing/0001493152-26-045371.json

SecFilingDex republishes SEC EDGAR data with provenance. EDGAR is the authoritative source. SecFilingDex is independent and not affiliated with the U.S. Securities and Exchange Commission. Nothing on this page constitutes investment, legal, tax, or other professional advice.